Drug Search Results
More Filters [+]

GSK-163090

Alternative Names: gsk-163090, gsk163090, gsk 163090
Latest Update: 2018-03-19
Latest Update Note: Clinical Trial Update

Product Description

GSK-163090 is potent, selective, and orally active 5-HT1A/B/D receptor antagonist. GSK163090 was found to combine potent in vivo activity with a strong preclinical developability profile, and on this basis it was selected as a drug candidate with the aim of assessing its potential as a fast-onset antidepressant/anxiolytic. GSK-163090 had been in phase II clinical trials by GlaxoSmithKline for the treatment of major depressive disorder (MDD) and anxiety disorders.Ê (Sourced from: https://drugs.ncats.io/drug/7XI927X82B)

Mechanisms of Action: 5-HT1A Antagonist,5-HT1B Antagonist,5-HT1D Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-163090

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Depressive Disorder, Major

Phase 1: Depressive Disorder|Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00896363

P2

Completed

Depressive Disorder, Major

2010-02-09

HTP110333

P1

Completed

Depressive Disorder, Major

2008-06-01

HTP103265

P1

Completed

Depressive Disorder

2007-12-01

NCT00536679

P1

Completed

Depressive Disorder

2007-11-05

Recent News Events

Date

Type

Title